{
    "nctId": "NCT00089661",
    "briefTitle": "AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer",
    "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Low Bone Mineral Density, Osteopenia",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 252,
    "primaryOutcomeMeasure": "Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12",
    "eligibilityCriteria": "* Histologically or cytologically confirmed adenocarcinoma of the breast\n* Subjects with early stage disease who are estrogen receptor positive and who have completed their treatment pathway (surgery, chemo-therapy, radiation, and/or hormone therapy) and are currently on or will initiate aromatase inhibitor therapy, and are expected to stay on aromatase inhibitor therapy for the duration of the 24-month study\n* All treatment pathway must be completed \u2265 4 weeks prior to study entry, and all acute toxic effect of any above therapy must be resolved to \u2264 Grade 1 by National Cancer Institution (NCI) Common Terminology Criteria for Adverse Events (CTCAE)\n* Female \\> 18 years of age\n* ECOG Performance status 0 and 1\n* Lumbar spine, total hip or femoral neck BMD equivalent to a t-score classification of -1.0 to -2.5\n* Subject is willing and able to provide signed consent before any study-specific procedure\n\nOther criteria also apply.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}